US regulatory status: approved. Molecular target: Integrin alpha-IIb/beta-3.
- Target
- Integrin alpha-IIb/beta-3
- Mechanism
- Integrin alpha-V/beta-3 inhibitor
pharma · Ependymoma, Medulloblastoma · chronically occluded coronary artery
Ishita Pharma -
ISTA Pharma Limited
Ishita Pharma - drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Mumbai, IN HQ
3 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Employees
- 3
- Programs
- 8
- Drugs
- 19
- Patents
- 0
Ishita Pharma - pipeline
Portfolio lens on 19 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Ishita Pharma - drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
axitinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
- Target
- Vascular endothelial growth factor receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to Ishita Pharma - in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Ishita Pharma -'s portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
Development asset linked to Ishita Pharma - in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Matrix metalloproteinase-1 inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor alpha agonist
-
Development asset linked to Ishita Pharma - in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Ishita Pharma - in public FDA and regional records.
-
orlistat
Alimentary tract and metabolism (A08)US regulatory status: approved. Molecular target: Gastric triacylglycerol lipase.
- Target
- Gastric triacylglycerol lipase
- Mechanism
- Pancreatic lipase inhibitor
-
Development asset linked to Ishita Pharma - in public FDA and regional records.
-
Development asset linked to Ishita Pharma - in public FDA and regional records.
-
Development asset linked to Ishita Pharma - in public FDA and regional records.
-
Development asset linked to Ishita Pharma - in public FDA and regional records.
-
Development asset linked to Ishita Pharma - in public FDA and regional records.